Adult patients with congenital heart disease and pulmonary arterial hypertension: First open prospective multicenter study of bosentan therapy

American Heart Journal

Volumn 150, Issue 4, 2005, Pages 716.e7-716.e12

  Schulze Neick, Ingram ^a   Gilbert, Nadine ^a   Ewert, Ralf ^b   Witt, Christian ^c   Gruenig, Ekkehard ^d   Enke, Beate ^e   Borst, Mathias M ^d   Lange, Peter E ^a   Hoeper, Marius M ^f  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e JUSTUS LIEBIG UNIVERSITY   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DRUG EFFICACY; EISENMENGER COMPLEX; ELECTROCARDIOGRAM; FEMALE; HEART VENTRICLE PRESSURE; HEMODYNAMICS; HUMAN; MALE; MEASUREMENT; MULTICENTER STUDY; OXYGEN CONSUMPTION; OXYGEN SATURATION; PARAMETER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TASK PERFORMANCE; TRANSCUTANEOUS OXYGEN MONITORING;

EID: 25844517634     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.07.005     Document Type: Article

References (29)

1. M. Beghetti Congenital heart disease and pulmonary hypertension Rev Port Cardiol 23 2004 273 281
2. W. Vongpatanasin, M.E. Brickner, and L.D. Hillis The Eisenmenger syndrome in adults Ann Intern Med 128 1998 745 755
3. H.W. Farber, and J. Loscalzo Pulmonary arterial hypertension N Engl J Med 351 2004 1655 1665
4. P. Wood The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt BMJ 46 1958 755 762
5. Guidelines on diagnosis and treatment of PAH. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur Heart J 25 2004 2243 2278
6. E.B. Berman, and R.J. Barst Eisenmenger's syndrome: current management Prog Cardiovasc Dis 45 2002 129 138
7. R.N. Channick, O. Sitbon, and R.J. Barst Endothelin receptor antagonists in pulmonary arterial hypertension J Am Coll Cardiol 43 2004 62S 67S
8. M. Clozel Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit? Ann Med 35 2003 605 613
9. N. Galie, A. Manes, and A. Branzi The endothelin system in pulmonary arterial hypertension Cardiovasc Res 61 2004 227 237
10. J.W. Cheng Bosentan Heart Dis 5 2003 161 169
11. R.N. Channick, G. Simonneau, and O. Sitbon Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2001 1119 1123
12. L.J. Rubin, D.B. Badesch, and R.J. Barst Bosentan therapy for pulmonary arterial hypertension N Engl J Med 346 2002 896 903
13. O. Sitbon, V. McLaughlin, and D. Badesch Comparison of two treatment strategies, first-line bosentan or epoprostenol, on survival in class III idiopathic pulmonary arterial hypertension [abstract] Am J Respir Crit Care Med 169 2004 A210
14. V.V. McLaughlin, O. Sitbon, and D.B. Badesch Survival with first-line bosentan in patients with primary pulmonary hypertension Eur Respir J 25 2005 244 249
15. E. Rosenzweig, D. Ivy, and A. Widlitz Effects of long-term bosentan in children with pulmonary arterial hypertension Am J Respir Crit Care Med 169 2004 A210
16. A. Keogh, P. Macdonald, and T. William Bosentan for the treatment of pulmonary arterial hypertension-6 month quality of life data [abstract] J Heart Lung Transplant 23 2004 S54
17. H.E. Tutar, A. Imamoglu, and S. Atalay Plasma endothelin-1 levels in patients with left-to-right shunt with or without pulmonary hypertension Int J Cardiol 70 1999 57 62
18. J. Lutz, M. Gorenflo, and M. Habighorst Endothelin-1- and endothelin receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease Clin Chem Lab Med 37 1999 423 428
19. I. Adatia, and S.G. Haworth Circulating endothelin in children with congenital heart disease Br Heart J 69 1993 233 236
20. G.G. Pietra, F. Capron, and S. Stewart Pathologic assessment of vasculopathies in pulmonary hypertension J Am Coll Cardiol 43 2004 25S 32S
21. G.H. Guyatt, M.J. Sullivan, and P.J. Thompson The 6 minute walk: a new measure of exercise capacity in patients with chronic heart failure CMAJ 132 1985 919 923
22. E.B. Rosenzweig, D. Kerstein, and R.J. Barst Long term prostacyclin for pulmonary hypertension with associated congenital heart defects Circulation 99 1999 1858 1865
23. S.M. Fernandes, J.W. Newburger, and P. Lang Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology Am J Cardiol 91 2003 632 635
24. J.L. Vachiery, N. Hill, and D. Zwicke Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension Chest 121 2002 1561 1565
25. M.A. Gatzoulis, P. Rogers, and L. Wei Safety and tolerability of bosentan in adults with Eisenmenger physiology Int J Cardiol 98 2005 147 151
26. R. Ibrahim, J. Granton, and S. Mehta Safety of bosentan in pulmonary arterial hypertension related to Eisenmenger physiology Presentation at the American Thoracic Society, 100. International Conference, Orlando, Florida, USA, May 2004
27. D. Cosgrove, S. Doherty, and S. Gaine The effect of bosentan in adults with pulmonary hypertension due to congenital heart disease Abstract 17S, presented at the WHO 3rd World Symposium of Pulmonary Arterial Hypertension 2003
28. R.J. Barst, D. Ivy, and J. Dingemanse Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension Clin Pharmacol Ther 73 2003 372 382
29. M. Humbert, C. van Lierop, and D.G. Kiely Long term safety profile of bosentan in patients with pulmonary arterial hypertension: results from the European surveillance program Data on file 2004 Actelion Pharmaceuticals, Ltd Allschwil (Switzerland)